GD2-CART cells and iPSC-derived GD2-CART cells (scRNA-Seq)
We showed that iPSC-derived GD2-CART therapy for SCLC was more effective than peripheral blood-derived GD2-CART. Here, we investigated the molecular difference between iPSC-derived GD2-CARTs and peripheral blood-derived GD2-CARTs. Overall design: We performed scRNA sequencing to understand the molecular difference between iPSC-derived GD2-CARTs and peripheral blood-derived GD2-CARTs